Company intelligence
Brand Institute
Where Great Brands Begin!
About Brand Institute
Brand Institute is the global leader in brand name and identity development. We provide a broad portfolio of services to our healthcare, consumer and business-to-business clients, including name development, trademark searches, market research, regulatory and visual identity solutions. As a company that provides specialized services to a sophisticated and discerning clientele, our people are paramount to our success. We staff each of our 18 global offices with experienced and knowledgeable professionals who provide attentive service and insightful strategic direction. Our Miami-based Headquarters Operational Team is the most experienced in our industry with over 400 years of combined branding experience. Our subsidiary, Drug Safety Institute (DSI), is led by former regulatory officials from the FDA, EMA and Health Canada. These industry thought leaders helped shape the global regulatory landscape as it pertains to proprietary (brand) and nonproprietary (USAN/INN) name development. They are now full-time Brand Institute employees who provide our clients with unparalleled guidance in the fields of name strategy, name safety research, labeling/packaging, and risk management. Our service-centric mindset, leading-edge team of regulatory professionals, and tenured operational staff have helped us become the #1 company in our category. We have partnered on the development of over 5,000 brand names and identities, and partner on approximately 80% of the drug names approved worldwide every year.
Verified activity
Signals from Brand Institute
6 published signals
Presence & Recognition
Brand Institute is represented by Divisional President of Western Europe and Emerging Markets, Mark Ghobry, and Vice President of Brand Development, Kasja Babic, at Nordic Life Science Days 2026 in Stockholm, Sweden.
Reported by Brand Institute
Legal & Regulatory
Brand Institute announced that AstraZeneca received accelerated FDA approval of ETCAMAH combination therapy in breast cancer for HR-positive, HER2-negative, locally advanced or metastatic patients upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy.
Reported by Brand Institute
Products & Services
Brand Institute launched Exilby, a cannabis-derived medication specifically indicated to treat chronic pain for patients in Germany and Austria.
Reported by Brand Institute